Holen Sie sich die Stockscreener-App
1.23
0.00%
0.00
Schlusskurs vom Vortag:
$1.23
Offen:
$1.22
24-Stunden-Volumen:
83,495
Relative Volume:
0.49
Marktkapitalisierung:
$46.47M
Einnahmen:
$22.33M
Nettoeinkommen (Verlust:
$-85.89M
KGV:
-0.5361
EPS:
-2.2942
Netto-Cashflow:
$-89.47M
1W Leistung:
+0.00%
1M Leistung:
-6.82%
6M Leistung:
-15.75%
1J Leistung:
-35.26%
1-Tages-Spanne:
$1.20
$1.24
1-Wochen-Bereich:
$1.18
$1.25
52-Wochen-Spanne:
$1.13
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Firmenname
Metagenomi Therapeutics Inc
Sektor
Branche
Telefon
(510) 871-4880
Adresse
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.23 | 46.09M | 22.33M | -85.89M | -89.47M | -2.2942 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-03-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-03-05 | Eingeleitet | TD Cowen | Outperform |
| 2024-03-05 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Metagenomi Therapeutics Inc Aktie (MGX) Neueste Nachrichten
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Metagenomi Therapeutics (MGX) Proxy filing Summary - Quartr
Metagenomi Therapeutics (MGX) AGM 2026 Summary - Quartr
Metagenomi Therapeutics (MGX) Q1 2026 earnings summary - Quartr
Metagenomi Therapeutics (MGX) Slides 2.7% as Stock Tests Key Support LevelTPO Profile - dars.gov.et
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Chardan Capital Initiates Metagenomi Therapeutics(MGX.US) With Buy Rating, Announces Target Price $5 - Moomoo
Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential - Investing.com
Metagenomi Therapeutics (MGX) Faces Continued Pressure Near Support LevelsSchiff Line - po-news-eg.net
Metagenomi Therapeutics (MGX) Holds Steady at $1.25 as Stock Consolidates Between Key LevelsSingle Stock ETF - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support, Eyes Resistance at $1.31Price Surge Stocks - dars.gov.et
Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Enterprise value to EBIT forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX) - TradingView
MGX Forecast — Price Target — Prediction for 2027 - TradingView
Metagenomi Therapeutics (MGX) Edges Lower, Testing Key Support at $1.13Sign of Strength - dars.gov.et
MGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Metagenomi Therapeutics Inc. (MGX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline InvestmentDividend Increase Stocks - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support; Faces Key Resistance at $1.26WMA Signal - Bölüm Sonu Canavarı
Metagenomi Therapeutics (MGX) Edges Lower as Stock Tests Key Support ZoneBull Pennant - Město Břeclav
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
MGX: Directors elected, auditor ratified, and all proposals approved with no shareholder questions - TradingView
Law firm investigates Metagenomi officers for p... - Pluang
Metagenomi Therapeutics (MGX) Slides 2.86% as Stock Tests Key Support LevelsSweep Order Flow - newsline.com
MGX Q1 2026 Earnings: Losses Widen Beyond Expectations as Pre-Revenue Biotech Focuses on PipelineEarnings Forecast Report - thelegaladvocate.com
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference - The Manila Times
Finanzdaten der Metagenomi Therapeutics Inc-Aktie (MGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):